Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19. Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms.
【저자키워드】 viral infection, Randomized controlled trials, 【초록키워드】 COVID-19, Treatment, coronavirus disease, Coronavirus disease 2019, Trial, Therapeutics, interferons, viral shedding, Diagnosis, Symptom, Symptoms, Moderate COVID-19, Randomized, Viral, symptom duration, placebo-controlled trial, Patient, Mild, Placebo, outpatients, group, single dose, Lambda, Outpatient, primary endpoint, mild to moderate, Mild to moderate COVID-19, type III interferon, 95% CI, 95% confidence interval, secondary endpoint, median time, hazard ratio, Elevation, single-blind, NCT04331899, Peginterferon Lambda-1a, SARS-CoV-2 viral shedding, Type III interferons, Effect, IMPROVE, not differ, significantly, conducted, receiving, determine, resolved, liver transaminase, outpatients with uncomplicated, subcutaneous dose, the median, 【제목키워드】 Treatment, randomized placebo-controlled trial, outpatients with uncomplicated,